57 Results for "

NAD levels

" in MedChemExpress (MCE) Product Catalog:
Products (57)

57 Results for "NAD levels" in MCE Product Catalog:

Cat. No.: HY-119159
CAS No.: 361465-74-9
Target:  

NAMPT Caspase Apoptosis

Research Areas:  

Cancer

AS1604498 is a highly specific competitive inhibitor of human NAMPT, with an IC50 of 44.4 nM. AS1604498 functionally inhibits NAMPT enzymatic activity, reduces nicotinamide mononucleotide production, decreases intracellular NAD levels, activates caspase 3/7 and induces cancer cell apoptosis. AS1604498 is applicable to research related to chronic myeloid leukemia .
loading...
    loading...
Cat. No.: HY-182025
Target:  

Endogenous Metabolite

Research Areas:  

Neurological Disease

NAD+ potentiator-1 (Compound R-4b) is a NAD potentiator. NAD+ potentiator-1 increases NAD levels in primary cortical neurons. NAD+ potentiator-1 is used for the research of neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-186178
CAS No.: 2766686-04-6
Target:  

CD38

CD38-IN-6 is an orally active CD38 inhibitor. CD38-IN-6 regulates NAD + metabolite levels in the liver of aged obese mice by increasing NAD + and NMN levels, and decreasing NAM and ADPR levels. CD38-IN-6 alleviates inflammatory responses in mice. CD38-IN-6 can be used for research related to obesity and inflammation .
loading...
    loading...
Cat. No.: HY-184206
Target:  

CD38

A-3190 is an orally active, blood-brain barrier permeable CD38 inhibitor, with an IC50 of 7.25 nM against human CD38 and 1.24 nM against mouse CD38. A-3190 is a derivative of A-8531 (HY-184021), and it forms covalent adducts with NAD + in the presence of CD38. A-3190 acts as an inducer of NAD + levels and an inhibitor of NAM and ADPR levels. A-3190 increases NAD + levels in the skin, lung, liver and brain of rodents, while reducing NAM and ADPR levels in brain tissues. A-3190 can be used in research related to multiple sclerosis, Parkinson's disease and Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-184246
CAS No.: 2791469-19-5
Target:  

NAMPT

Research Areas:  

Neurological Disease

SR-34831 is a NAMPT activator, NAD level stabilizer and neuroprotective agent. SR-34831 enhances the enzymatic activity of human NAMPT, prevents intracellular NAD depletion, and counteracts neuronal death induced by toxic misfolded prion proteins. SR-34831 exhibits metabolic stability in human liver microsomes and can be used for the research of protein misfolding neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-187347
Target:  

PROTACs NAMPT

Research Areas:  

Cancer

PROTAC NAMPT Degrader-31 is a PROTAC degrader that targets and degrades NAMPT by recruiting cereblon. It exhibits DC50 values of 9.31 nM and 12.54 nM against NAMPT in MDA-MB-231 and 4T1 cells, respectively, and an IC50 value of 15.05 nM for NAMPT enzymatic activity. PROTAC NAMPT Degrader-31 induces NAMPT degradation via the ubiquitin-proteasome system, inhibits NAMPT enzymatic activity, and reduces NAD + levels through the NAD + salvage pathway. It can be used in research related to triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-184021
Target:  

CD38

Research Areas:  

Neurological Disease

A-8531 is an orally active CD38 inhibitor with IC50 values of 1.10 nM against human CD38, IC50 values of 2.93 nM against mouse CD38, and a human Ka of 0.32 nM. A-8531 exerts its inhibitory activity via its 4-pyridine reactive warhead interacting with the CD38 substrate NAD +, and binds stably to CD38 only in the presence of NAD +, with a binding KD of 0.32 nM as detected by SPR. A-8531 dose-dependently increases NAD + levels in mouse skin, lung and liver tissues, while simultaneously reducing the contents of NAM and ADPR in these tissues. A-8531 derivative A-3190 (HY-184206) has blood-brain barrier penetration. A-8531 can be used in studies related to neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-B0150G
CAS No.: 98-92-0
Synonyms: Niacinamide (GMP); Nicotinic acid amide (GMP)
Nicotinamide (GMP) (Niacinamide (GMP)) is the GMP level of Nicotinamide (HY-B0150). GMP guidelines are used to produce Nicotinamide (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
loading...
    loading...
Cat. No.: HY-W744757
CAS No.: 113950-01-9
Synonyms: Niacinamide-15N; Nicotinic acid amide-15N
Nicotinamide- 15N (Niacinamide- 15N) is the deuterium labeled Nicotinamide (HY-B0150). Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity.
loading...
    loading...
Cat. No.: HY-B0150S4
Synonyms: Niacinamide-13C,15N; Nicotinic acid amide-13C,15N
Nicotinamide- 13C, 15N (Niacinamide- 13C, 15N) is the 13C- and 15N-labeled Nicotinamide (HY-B0150). Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
loading...
    loading...
Cat. No.: HY-50876A
CAS No.: 2727965-45-7
Synonyms: FK866 hydrochloride; APO866 hydrochloride
Daporinad (FK866) hydrochloride is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad hydrochloride depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad hydrochloride causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad hydrochloride induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad hydrochloride can be used for the study of myeloma, liver cancer, and immunosuppression .
loading...
    loading...
Cat. No.: HY-182062
CAS No.: 931366-46-0
Target:  

NAMPT E1/E2/E3 Enzyme

Research Areas:  

Neurological Disease

NAMPT activator-9 (Compound DIPM) is an allosteric, non-competitive NAMPT activator, with an EC50 of 3.366 μM against hNAMPT. NAMPT activator-9 enhances the enzymatic activity of NAMPT via an allosteric, non-competitive mechanism. NAMPT activator-9 increases intracellular NAD + levels. NAMPT activator-9 restores myotube diameter and reduces the expression of atrophy markers Atrogin-1 and MuRF1. NAMPT activator-9 is applicable to research related to muscle atrophy .
loading...
    loading...
Cat. No.: HY-W008927
CAS No.: 361377-29-9
Fluoxastrobin is a fungicide. By binding to NAD-dependent epimerase/dehydratase, Fluoxastrobin interferes with electron transport, reduces ATP production and inhibits mycelial growth, thereby effectively controlling foliar diseases of tea plants. Fluoxastrobin induces oxidative stress by increasing ROS levels and lipid peroxidation, causes DNA damage and promotes apoptosis; meanwhile, it shows high acute toxicity to Danio rerio embryos and larvae. Fluoxastrobin can be used in research related to tea foliar diseases (including tea red leaf spot and tea gray leaf spot) .
loading...
    loading...
Cat. No.: HY-184396
GR2-128 is a dual inhibitor targeting MLK3 and NAMPT with IC50 values of 84 nM and 14 nM, respectively. GR2-128 inhibits downstream JNK/c‑Jun signaling and reduces NAD + levels. GR2-128 exhibits antiproliferative and pro-apoptotic activities in triple-negative breast cancer cells without significant toxicity to normal cells. GR2-128 suppresses tumor growth, reduces macrophage and neutrophil infiltration, and increases tumor T-cell markers in a syngeneic mouse model, and can be used for triple-negative breast cancer research .
loading...
    loading...
Cat. No.: HY-W615108BR
CAS No.: 108347-85-9
β-Nicotinamide mononucleotide, reduced form (disodium) (Standard) is the analytical standard of β-Nicotinamide mononucleotide, reduced form (disodium) (HY-W615108B). This product is intended for research and analytical applications. β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD+ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .
loading...
    loading...
Cat. No.: HY-184650
Target:  

SHP2 NAMPT Apoptosis ERK

Research Areas:  

Cancer

SHP2/NAMPT-IN-1 is an orally active dual inhibitor of SHP2 and NAMPT, with IC50 values of 30.5 nM and 24.4 nM, respectively. SHP2/NAMPT-IN-1 reduces NAD+ levels and p-ERK expression by inhibiting NAMPT. SHP2/NAMPT-IN-1 can inhibit the migration and colony formation of MDA-MB-231 cells and promote apoptosis. SHP2/NAMPT-IN-1 has anti-proliferative activity against a variety of tumor cell lines and can reverse PD-L1-mediated T-cell immunosuppression. SHP2/NAMPT-IN-1 can be used for breast cancer research .
loading...
    loading...
Cat. No.: HY-184969
NUCC-0227579 is a VHL-recruiting PROTAC degrader targeting CD73, with a DC50 of 0.32 μM. NUCC-0227579 synergistically mediates CD73 degradation through the ubiquitin-proteasome pathway and the lysosomal pathway. NUCC-0227579 inhibits the conversion of AMP to adenosine, abrogates adenosine-mediated immunosuppression, upregulates the activities of the NF-κB and NFAT pathways, and enhances the secretion, activation and proliferation levels of IFN-γ and TNF-α. NUCC-0227579 downregulates NAD + synthesis in tumor cells, and inhibits the proliferation, migration and adhesion abilities of tumor cells under glutamine-deficient conditions. NUCC-0227579 significantly suppresses tumor growth in a humanized NSG mouse model of triple-negative breast cancer .
loading...
    loading...